Adial Pharmaceuticals (Nasdaq: ADIL), a clinical-stage biopharmaceutical company headquartered in Glen Allen, Virginia, announced submission of an application for consideration under the FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04, a genetically targeted serotonin-3 (5-HT3) receptor antagonist in development for Alcohol Use Disorder (AUD) in heavy-drinking patients with specific genotype profiles.
The CNPV, announced by the FDA in 2025, is a pilot mechanism distinct from established designations such as Fast Track or Breakthrough Therapy. If granted, a voucher would enable rolling review, earlier agency interaction, and a potential review timeline of approximately one to two months following submission of a complete package, compared to the standard ten to twelve months. Vouchers issued under the program are not transferable. AD04 previously received FDA Fast Track Designation for AUD, making the CNPV application a further regulatory step for the program.
AD04 is built around a precision-medicine framework: patient selection relies on a proprietary companion diagnostic that identifies individuals carrying a defined five-marker genetic profile spanning serotonin transporter and serotonin-3AB receptor variants. Adial is planning a new Phase III clinical trial program in this genotype-defined AUD population, with no start date disclosed in the current announcement.
The most detailed public clinical evidence for AD04 comes from the Phase III ONWARD trial, a six-month, 25-site, randomized, placebo-controlled study enrolling adults with DSM-5-categorized AUD stratified into heavy and very heavy drinking endophenotypes, all genotype-matched using the companion diagnostic. AD04 was administered at 0.33 mg twice daily alongside brief psychosocial counseling. Results published in the European Journal of Internal Medicine in June 2024 showed a statistically significant reduction in the monthly percentage of heavy drinking days versus placebo in the heavy-drinking subgroup. The very heavy drinking subgroup did not reach statistical significance, an outcome the investigators attributed to a floor effect: both arms reduced mean heavy drinking days by more than 50% from a baseline of approximately ten drinks per drinking day. Exact p-values and mean percentage reductions were not disclosed in publicly available materials. Adverse events in the AD04 arm were comparable to placebo, dropout rates were low, and a parallel April 2024 analysis of liver biochemical parameters from ONWARD found no clinically meaningful difference in liver function tests between arms.
A pharmacokinetics study designated AD04-103, with results reported in November 2024, confirmed dose-proportional exposure, relative bioavailability versus a reference ondansetron 4 mg formulation, and no food effect, completing elements of the clinical package relevant to a Phase III design meeting with the FDA.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team
Explore more at AllSci News: https://allsci.com/news/